Nishant Tiwari Reports Zero Relapses with Scheduled Rituximab in TTP
Nishant Rajendra Tiwari, Hematology-Oncology Fellow at OU Health Stephenson Cancer Center, posted on X:
”Pre-emptive rituximab stopped relapses in our iTTP patients.
After 3-5 prior relapses each and 1 exacerbation, 4 patients received scheduled Rituximab for 2 years.
Result? No relapses during a median 17.5-month follow-up. (Range 3 – 68 months)
This is a big deal for a tough disease. Grateful to my mentor, Dr. Khawandanah and our team. More studies are needed, but hope is here.
Super thankful to all of our mentor – Dr James N George, truly a difference maker in these patients, and in his mentees’ careers.
The fellows at OU Health Stephenson Cancer Center continue to shine; we have the best leadership and the fellowship program director (Dr. Sami Ibrahimi).”
Keep up with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?